Interaction between Pseudorabies Virus and Heparin/Heparan Sulfate
PSEUDORABIES VIRUS MUTANTS DIFFER IN THEIR INTERACTION WITH HEPARIN/HEPARAN SULFATE WHEN ALTERED FOR SPECIFIC GLYCOPROTEIN C HEPARIN-BINDING DOMAIN*

Edward TrybalaDagger , Tomas BergströmDagger §, Dorothe Spillmann, Bo SvennerholmDagger , Shannon J. Flynnpar , and Patrick Ryanpar

From the Dagger  Department of Clinical Virology, University of Göteborg, Guldhedsgatan 10B, S-413 46 Göteborg, Sweden, the  Department of Medical and Physiological Chemistry, University of Uppsala, S-751 23 Uppsala, Sweden, and the par  Department of Microbiology and Immunology, University of Tennessee, Memphis, Tennessee 38163

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell surface heparan sulfate serves as an initial receptor for a number of herpesviruses including pseudorabies virus (PrV). It has been demonstrated that the heparan sulfate-binding domain of PrV glycoprotein C is composed of three discrete clusters of basic residues corresponding to amino acids 76-RRKPPR-81, 96-HGRKR-100, and 133-RFYRRGRFR-141, respectively, and that these clusters are functionally redundant, i.e. each of them could independently support PrV attachment to cells (Flynn, S. J., and Ryan, P. (1996) J. Virol. 70, 1355-1364). To evaluate the functional significance of each of these clusters we have used PrV mutants in which, owing to specific alterations in glycoprotein C, the heparan sulfate-binding site is dominated by a single specific cluster. These mutants exhibited different patterns of susceptibility to selectively N-, 2-O-, and 6-O-desulfated heparin preparations in virus attachment/infectivity assay. Moreover PrV mutants differed as regard to efficiency of their attachment to and infection of cells pretreated with relatively low amounts of heparan sulfate-degrading enzymes. Furthermore glycoprotein C species, purified from respective mutants, bound heparin oligosaccharide fragments of different minimum size. These differences suggest that specific clusters of basic amino acids of the heparan sulfate-binding domain of glycoprotein C may support PrV binding to different structural features/stretches within the heparan sulfate chain.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Heparan sulfate (HS)1 glycosaminoglycan chains, ubiquitous components of cell surfaces and extracellular matrices, have been demonstrated to serve as an initial receptor for a number of herpesviruses, including herpes simplex virus type 1 and type 2 (1), pseudorabies virus (PrV) (2), bovine herpesvirus 1 (3, 4), varicella zoster virus (5), human cytomegalovirus (6, 7), and bovine herpesvirus 4 (8). Thus, evolutionary distant herpesviruses follow a common strategy to initiate infection of susceptible cells. An early study emphasized importance of the charge density of heparin/HS for interaction with herpes simplex virus (9), while recent competition experiments demonstrated that preparations of selectively modified heparin differentially inhibited attachment to cells of herpes simplex virus type 1 and 2 (10, 11) and PrV (12). However, several facets of herpesviral interactions with heparin/HS remain obscure. These include involvement of specific structural features of heparin/HS, a possible association of virus binding to HS with further steps of herpesvirus entry into the cells, the importance of HS recognition for the specific cell and tissue tropism of different herpesviruses, and functional aspects of the HS-binding sites of herpesvirus glycoprotein C (gC).

According to one of the molecular concepts of glycosaminoglycan recognition by proteins, consensus sequences comprising clusters of basic and hydropathic amino acid residues have been regarded as primary heparin/HS binding units (13). HS/heparin-binding proteins frequently contain more than one functional cluster of basic amino acid residues (for review, see Ref. 14). Molecular models available for several such proteins show that these clusters are assembled in a specific region on a surface of folded protein to form either an elongated domain that could function in accommodation of linear structures of glycosaminoglycan chains (15, 16) or a more complex domain that can bind with high specificity to relatively short stretches within heparin/HS (17, 18). Since heparin/HS binding sequences of different proteins carry distinct compositions of amino acid residues that interspace or flank positively charged amino acids, specific clusters of basic residues may differentially contribute toward an overall heparin/HS binding activity or toward a regulation of protein-glycosaminoglycan interaction.

PrV, a pathogen closely related to herpes simplex virus, causes Aujeszky's disease in swine. In addition PrV can cause a deadly disease in many different animals except for equines and higher primates. It has been shown that gC of the virus envelope is the major component that interacts with cell surface HS, thus mediating efficient virus attachment to the cells (2, 19, 20). gC-null strains of PrV can still infect the cells, albeit with a significantly lower attachment efficiency than wild-type gC-positive virus. The HS-binding domain of PrV gC has been delimited to the amino-terminal one-third fragment of this glycoprotein (21). Mutational analysis of PrV gC revealed that the three clusters of basic amino acid residues at locations 76-RRKPPR-81, 96-HGRKR-100, and 133-RFYRRGRFR-141, respectively, are the major components of the HS-binding domain (22). Interestingly, these clusters seemed to function redundantly, since PrV mutants whose gC contains double amino acid substitutions in any two clusters, i.e. it retains intact only one specific cluster, could still efficiently attach to cell surface HS (22). In the present study we took advantage of this observation to examine the mode of interaction between heparin/HS and PrV mutants that contain HS-binding site of gC dominated by a single specific cluster of basic residues. Our competition experiments and direct binding assays revealed a number of differences in interaction between the respective PrV gC mutants and heparin/HS.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Chondroitinase AC I Flavo (chondroitin AC lyase; EC 4.2.2.5) was obtained from the Seikagaku Co. (Tokyo, Japan). Chondroitinase ABC (chondroitin ABC lyase; EC 4.2.2.4), heparinase I (heparin lyase I; heparinase; EC 4.2.2.7), and heparinase III (heparitin sulfate lyase III; heparitinase, EC 4.2.2.8) were from Sigma. Na235SO4 (up to 100 mCi/mmol) and NaB3H4 (24-28 Ci/mmol) were from Amersham Corp. Anti-PrV gC monoclonal antibodies F2E3.1E8 and F3E3.1C4 were kindly provided by Dr. N. Coe (National Animal Disease Center, Ames, IA).

Cells and Viruses-- Rabbit kidney (RK-13) and Madin-Darby bovine kidney (MDBK) cells were cultivated in Eagle's minimum essential medium (EMEM) supplemented with 4% heat-inactivated fetal bovine serum. The wild-type PrV Becker (PrV-Be) strain (23) and its derivatives PrV580, PrV581, PrV582, and PrV583 (22) were used. Each of these mutants carry several substitutions for specific basic amino acid residues within the three major heparin/HS-binding subunits of the one-third amino-terminal portion of PrV gC (22) (Table I). To determine the virus particle/infectivity ratio, PrV mutants were propagated in RK-13 cells, harvested 24 h after infection, and purified by centrifugation through a three-step discontinuous sucrose gradient as described (19). The viral infectivity (plaque assay) was determined by titration of the purified virus preparations on RK-13 cells. After a 1-h adsorption period at 37 °C, the unadsorbed virus inoculum was removed, and the cells were washed two times with EMEM and overlaid with 1% methylcellulose solution in EMEM. Based on the determination of DNA content in the purified virus preparations (20), the number of virus particles to plaque forming unit (pfu) ratios were 2.6 × 102 for PrV-Be, 1.8 × 103 for PrV580, 3.4 × 102 for PrV581, 4.5 × 103 for PrV582, and 8 × 103 for PrV583.

Modified Heparin Compounds-- Heparin modifications were performed on bovine lung heparin (Table II) that had been isolated and purified as described (24). Selective 2-O-desulfation was performed by lyophilization at pH 12.5 as described (25). N-Desulfation was performed on the pyridiminium salt of heparin in Me2SO:H20 (19:1) at 50 °C for 90 min (26). Preferential 6-O-desulfation was performed in Me2SO:MeOH (9:1) at 93 °C for 2 h (Table II; preparations 4 and 5) and at 93 °C for 8 h (preparations 7 and 8) (27). O-Desulfated heparin chains were N-resulfated (28), whereas N-desulfated heparin was N-acetylated (29) as described. Even-numbered heparin oligosaccharides were obtained by partial deaminative cleavage of the polysaccharide at the N-sulfated glucosamine units by nitrous acid at pH 1.5, followed by reduction of the resulting 2,5-anhydro-D-mannose residues with cold or 3H-labeled NaBH4 (30) and separation on a Bio-Gel P-10 column (1 × 140 cm) in 0.5 M NH4HCO3. The specific activity of the end-labeled heparin oligomers was ~0.5 × 106 cpm/nmol chain.

Isolation of HS Chains-- Freshly confluent monolayers of MDBK cells were metabolically labeled for 48 h with 50 µCi/ml Na235SO4 in sulfate-free EMEM supplemented with 10% fetal calf serum and antibiotics. Cell-associated HS chains were isolated according to the procedure described by Lyon et al. (31).

Purification of PrV gC-- Confluent, dense monolayers of 4-day-old RK-13 cells were infected with PrV, and when the cytopathic effect was advanced, the cells were spun down by low speed centrifugation and stored at -70 °C. The virus was pelleted from the medium by centrifugation at 160,000 × g for 1 h. Both virus and infected cell pellets were combined and resuspended in cold 0.02 M Tris-HCl buffer, pH 7.5, containing 1% sodium deoxycholate, 2% Nonidet P-40, 2 mM EDTA, and 2 mM 4-(2-aminoethyl)benzenesulfonyl fluoride. The mixture was homogenized with several strokes of a Dounce homogenizer and left on ice for 1 h. The unsolubilized material was pelleted by centrifugation at 130,000 × g for 1 h, and the supernatant was circulated for 1 h through an immunosorbent column containing either F2E3.1E8 or F3E3.1C4 anti-PrV gC monoclonal antibody (32). Subsequently the column was washed with 0.02 M Tris-HCl, pH 7.5, containing 0.1% Nonidet P-40, 0.5 M NaCl, and 2 mM EDTA. The adsorbed material was eluted with 0.1 M glycine HCl, pH 2.4, and immediately neutralized with 1 M Tris-HCl, pH 8.0. To exchange the buffer into PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4), the eluted material was centrifuged over 10,000-Da microcentrifugal concentrator (Palfiltron). Protein concentration was determined according to the standard Lowry method (DC protein assay kit, Bio-Rad).

PrV Attachment in the Presence of Modified Heparin-- All experiments were carried out at 4 °C (cold room). Serial 5-fold dilutions of the indicated compound in 2 ml of Hanks' balanced salt solution were mixed with 200 µl of the same medium containing ~200 pfu of PrV and incubated for 15 min. Confluent, dense monolayers of MDBK (3-day-old) cells in six-well plates, precooled for 20 min at room temperature and for 20 min at 4 °C, were washed with 2 ml of Hanks' medium and then 1-ml portions of the virus/heparin mixture were added. Following an adsorption for 1 h, the cells were washed twice with 2 ml of Hanks' medium and overlaid with 4 ml of EMEM containing 1% methylcellulose, 2% fetal bovine serum, and antibiotics. The plaques were stained with crystal violet solution after 3 days of incubation at 37 °C.

PrV Attachment to Heparinase- or Heparitinase-treated Cells-- Confluent monolayers of 2-day-old MDBK cells in six-well plates were washed two times with 2 ml of Hanks' medium, and 1-ml portions of the same medium containing the indicated number of heparinase or heparitinase units were added. Following incubation at 37 °C for 1 h and at 4 °C for 20 min, the cells were washed two times with 2 ml of cold Hanks' medium, and ~200 pfu of PrV in 1 ml of Hanks' medium were added. Following virus adsorption for 1 h at 4 °C, the cells were washed twice with 2 ml of Hanks' medium and overlaid with 4 ml of methylcellulose solution. The plaques were stained with crystal violet solution after 3 days of incubation at 37 °C.

Binding of Glycosaminoglycans to PrV gC-- Purified gC (1.5 µg) in 0.2 ml of PBS supplemented with 0.05% bovine serum albumin (BSA) was mixed with ~5000 cpm of MDBK cell-specific [35S]HS and incubated for 2 h at room temperature. Bound glycosaminoglycan was trapped on nitrocellulose filters as described (33). For heparin oligosaccharide binding, purified gC (1.5 µg) in 0.2 ml of PBS-BSA was mixed with ~5000 cpm of [3H]heparin oligosaccharide composed of 4 through 18 monosaccharide units. Following incubation at 4 °C for 90 min, the mixtures were transferred to microcentrifugal concentrators (Microsep) with 10,000/30,000-Da cutoff and centrifuged in a horizontal rotor at 3400 × g for 30 min at 4 °C. Subsequently using the same centrifugation conditions the filters were washed two times with 0.2 ml of PBS, and the bound heparin oligosaccharides were eluted with 0.2 ml of 2 M NaCl. The eluted fractions were diluted in 1 ml of water and transferred to liquid scintillation vials for quantification of radioactivity.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

PrV gC Attachment Mutants Differ in Their Sensitivity to Modified Heparin Compounds-- Several PrV mutants in which the HS-binding site of gC is dominated by a specific cluster of basic amino acid residues (22) were selected for competition experiments (Table I). In PrV580C-III, PrV581C-II, and PrV582C-I two out of the three clusters of basic residues that compose the HS/heparin-binding domain were disrupted by simultaneous replacement of two pairs of basic amino acid residues with neutral amino acids. Consequently, PrV580C-III carries the 133-RFYRRGRFR-141 cluster (Cluster-III) intact, PrV581C-II the 96-HGRKR-100 cluster, and PrV582C-I the 76-RRKPPR-81 cluster as a dominant HS-binding sequence of gC. Of note, these mutants showed reactivity with three different anti-gC monoclonal antibodies (22) that recognize conformation-dependent epitopes and that have been reported (20) to be able to inhibit PrV binding to cells. The retention of all three epitopes by the gC mutants reduces the likelihood that amino acid substitutions introduced significant alterations in the folding of gC. Since more profound gC changes such as deletion of the entire 133-RFYRRGRFR-141 sequence or the 96-HGRKR-100 cluster abolished gC reactivity with some monoclonal antibodies (22), such mutants were not included in the present study. PrV583, whose gC contains dysfunctional HS-binding domain due to double substitutions for arginine and/or lysine residue in each of the three clusters of basic amino acids (Table I), was used as control. As shown earlier on pig kidney cells (22) and repeated in the present study on MDBK cells (Fig. 1) parental PrV-Be as well as PrV580C-III, PrV581C-II, and PrV582C-I were attachment-proficient, whereas the control PrV583 strain demonstrated significantly lower attachment efficiency, manifested by the fact that ~65% of input virus could be removed from cell surface by simple washing the cells with Hanks' medium (Fig. 1). In this respect PrV583 resembles gC-null strains of PrV.

                              
View this table:
[in this window]
[in a new window]
 
Table I
PrV gC attachment mutants
Data from Flynn and Ryan (22). Indicated are double amino acid substitutions introduced within the specific clusters of basic amino acid residues of the HS-binding domain of viral gC. Underlined are clusters of basic amino acids that dominate in gC of the respective mutant.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Attachment of PrV gC mutants to MDBK cells. Approximately 200 pfu of the respective mutant strain in 1 ml of cold Hanks' medium were added to confluent, 3-day-old cultures of MDBK cells and left for attachment at 4 °C for 1 h. Subsequently the medium was aspirated, and the cells were either washed three times with 2 ml of cold Hanks' medium or left untreated and overlaid with standard methylcellulose solution. The viral plaques were counted after incubation of cells for 3 days. The number of pfu formed on Hanks' medium-washed cells is expressed as a percentage of untreated controls. Values shown are means of three replicates.

The pattern of inhibition of PrV-Be attachment to MDBK cells by desulfated heparins (Fig. 2; for IC50 values, see Table II) resembles that observed previously on RK-13 cells, except that N-desulfated heparin was somewhat more active on the latter cells (12). Thus, singular removal of only one type of sulfate groups affected the competition capacity of heparin only slightly with 6-O-desulfated heparin being the least active competitor followed by 2-O- and N-desulfated heparin (Fig. 2; compare samples 2, 3, and 4). This weak PrV preference for the specific sulfate groups, i.e. 6-O-sulfates > 2-O-sulfates > N-sulfates is further confirmed by the observation that modified heparin sample 6, which contains 6-O-sulfate groups as a major sulfate component left, was more active than sample 5, which retains 2-O-sulfates as predominant groups, and the preparation carrying predominantly N-sulfates (#7). Native heparin poorly inhibited attachment of control PrV583 strain. In the presence of the highest concentration of heparin tested (25 µg/ml), an average number of PrV583 plaques expressed as a percentage of plaques formed in the absence of heparin was 89 (±27) (three experiments).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of modified heparin preparations on PrV-Be, PrV580, PrV581, and PrV582 attachment to and infection of MDBK cells. Virus attachment assays were performed in the presence of 5-fold (log5) increasing concentrations of modified heparin as described under "Experimental Procedures." The number of pfu is expressed as a percentage of the average number of plaques formed in the absence of competitor. At least two separate experiments were carried out in duplicate for each sample. Numbers that follow each sample refer to Table II.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Structural features and antiviral activities of modified heparin compounds

The effects of modified heparin samples on PrV580C-III, PrV581C-II, and PrV582C-I attachment to MDBK cells are shown in Fig. 2. Although an overall PrV preference for different sulfate groups of heparin, i.e. 6-O- > 2-O- > N-sulfates remained similar with all mutant strains, these viruses exhibited different patterns of sensitivity to heparin samples, especially evident when the competition capacities of native heparin versus desulfated heparin preparations are compared. PrV581C-II, PrV582C-I, and to lesser extent, PrV580C-III, were less efficiently inhibited by native heparin than parental PrV-Be strain. However, PrV580C-III exhibited higher sensitivity than PrV-Be to all the desulfated samples of heparin (compare samples 2-7). In fact both N- and 2-O-desulfated samples appeared to be slightly better inhibitors than native heparin of PrV580C-III binding. Quite the opposite pattern was observed in PrV581C-II. Selectively N-, 2-O-, and 6-O-desulfated heparin compounds were ~2 orders of magnitude less active competitors of the binding of this mutant than PrV580C-III. Thus, our results that selectively desulfated heparin samples were poor inhibitors of PrV581C-II but efficient inhibitors of PrV580C-III binding suggest that PrV581C-II may show preference for more extensively sulfated stretches within the HS chain than those required for PrV580C-III. PrV582C-I exhibited intermediate sensitivity to modified heparins. While selectively N-desulfated and 2-O-desulfated heparin preparations exhibited comparable competition capacities when tested with PrV580C-III, PrV581C-II, and the parental strain, there was a 5-fold difference between relative potencies of these samples with PrV582C-I (Fig. 2; Table II). This suggests that an overall binding preference for the specific sulfate groups might be somewhat changed in this mutant.

PrV gC Attachment Mutants Differ in Their Abilities to Bind Heparin Oligosaccharides of Different Size-- Differential susceptibility of PrV mutants to desulfated heparin samples suggested that specific subunits of the HS-binding domain of gC might show preference for different structural features of heparin/HS. To verify this interpretation, gCs purified by immunoaffinity chromatography from the respective PrV mutants were tested for ability to bind 3H-labeled size-fractionated heparin oligosaccharides composed of 4 through 18 monosaccharide units. Mutated gCs showed different patterns of binding heparin fragments (Fig. 3). PrV-Be gC bound significant proportions of 8-mer and near-maximal levels of 10-mer and larger fragments. Of all the mutants, only PrV581C-II demonstrated a similar binding pattern as the wild-type protein, although slightly larger fragments were required for efficient binding. The remaining mutants exhibited a clearly lower capacity to bind to short heparin fragments and were demonstrating a linear dependence of affinity and fragment length.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of PrV gC to heparin oligosaccharides. Glycoprotein C (1.5 µg), purified from the respective PrV mutant, was incubated in 0.2 ml of PBS-BSA with approximately 5000 cpm of 3H-labeled heparin oligosaccharide at 4 °C for 90 min. 3H-Labeled heparin fragments associated with gC were recovered by passing the mixtures through the filters as described under "Experimental Procedures." Control mixtures without gC gave less than 100 cpm. Values are means of two replicates from two separate experiments.

PrV583 gC bound little but definite amounts of some heparin fragments. In a separate experiment we noticed that gC from PrV583 weakly interacted with heparin oligosaccharides, since repeated cycles of washing the gC-oligosaccharide complexes that had been retained on filters continuously removed some amounts of labeled oligosaccharide (data not shown). This is in line with the observation that a significant proportion of input PrV583 virions can be removed from cell surfaces by simple washing the cells with PBS (Fig. 1).

PrV gC Attachment Mutants Differ in Their Binding to Heparitinase- or Heparinase-treated cells-- Knowing that each of specific clusters of basic amino acid residues could separately support efficient PrV attachment to cell, we were interested in a purpose for the presence of redundant HS-binding subunits in wild-type PrV gC. To this end gCs purified from the respective mutant and wild-type strain were tested for their ability to bind HS isolated from MDBK cells. Under conditions described under "Experimental Procedures," PrV-Be gC bound 32% (±4%), PrV580C-III gC 7% (±1%), PrV581C-II gC 10% (±1%), and PrV582C-I gC bound 6% (±2%) of input HS (three experiments). Thus, the presence of all three clusters of basic residues endows parental gC with high HS binding capacity. To examine whether and under which conditions the high HS-binding ability of parental gC is beneficial for PrV interaction with cell surface HS, we compared the binding of wild-type and mutant strains to cells pretreated with relatively low amounts of HS-degrading enzymes (Fig. 4). PrV gC mutants differed in their abilities to attach to and to infect of enzyme-treated cells. Similar tendencies were observed with both heparinase and heparitinase. The binding of PrV582C-I was most affected, then followed PrV580C-III, and the binding of PrV581C-II was only slightly reduced as compared with parental strain PrV-Be. Pretreatment of cells with heparinase and heparitinase had little and moderate effects, respectively, on binding of the control PrV583 strain. Note that the two PrV mutants that have been the most affected by heparinase/heparitinase, i.e. PrV582C-I and PrV580C-III required relatively long heparin oligosaccharides for efficient binding (Fig. 3).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Attachment of PrV gC mutants to MDBK cells pretreated with heparinase or heparitinase. Confluent 2-day-old monolayers of MDBK cells in six-well plates were treated with the indicated numbers of heparinase or heparitinase units (Sigma units; one IU corresponds to ~600 Sigma units) as described under "Experimental Procedures." The number of pfu is expressed as a percentage of the average number of plaques formed in mock-treated monolayers. Values shown are means of four replicates from two separate experiments (heparitinase) or two replicates from single experiment (heparinase).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

It has been demonstrated that the HS-binding domain of PrV gC is composed of three discrete clusters of basic amino acid residues and that each of these clusters could independently support PrV attachment to cells (22). In this work we attempted to define whether this design of the HS-binding domain would provide PrV gC with an ability to interact with different structural features of heparin/HS. To this end, we have used PrV mutants (22) in which gC contains intact only a single specific cluster. Two remaining clusters were disrupted by double substitutions of neutral amino acids for basic amino acid residues. Due to the fact that only two out of several basic amino acids in each cluster had been altered, a residual binding activity of the mutated cluster cannot be excluded. However, we restricted our analysis to these mutants because (i) amino acid substitutions, in contrast to the entire cluster deletion, introduced little or no changes in the conformation of gC as detected with monoclonal antibodies, and (ii) mutations caused significant functional impairments of the clusters, since the mutant virus in which all three clusters of the HS-binding domain of gC were disrupted poorly attached to cells. In addition we have used modified heparin compounds to relate specific amino acid sequence of the respective cluster with binding preferences for specific sulfate groups and chain length of heparin.

Our results suggest that PrV mutants whose gC contains a HS-binding site dominated by a single specific cluster of basic residues may preferentially interact with different structural features of heparin/HS. This stems from the observations that mutant viruses exhibited different patterns of sensitivity to selectively desulfated heparin compounds in cell attachment assays and that gC, purified from the respective mutants, differed in their abilities to bind size-fractionated heparin oligosaccharides. Inhibition of attachment of the PrV581C-II mutant to cells was strongly dependent on the presence of all, i.e. N-, 2-O-, and 6-O-sulfate groups in the heparin preparation. When either of the sulfate group was removed, a drastic reduction in the potency of the inhibitor was observed, suggesting that the C-II cluster of the HS-binding domain of gC may require a highly sulfated stretch within HS for an efficient interaction to occur. gC isolated from PrV581C-II bound heparin oligosaccharides almost as efficiently as wild-type gC. Heparin 8-10-mer fragments were the shortest oligosaccharides binding and a near-maximal binding capacity reached with oligosaccharides composed of 12 monosaccharide units.

In a sharp contrast to PrV581C-II, selective N-, 2-O-, or 6-O-desulfation of did not decrease heparin ability to inhibit attachment to cells of PrV580C-III. Interestingly, two heparin derivatives, i.e. N- and 2-O-desulfated preparations, were even somewhat more efficient than native heparin at inhibition of this mutant. This suggests that a high density of sulfate groups within glycosaminoglycan chain is not required for interaction with PrV580C-III. In addition gC, isolated from PrV580C-III, required longer heparin oligosaccharides than gC from PrV581C-II for effective binding. Efficient inhibition of PrV580C-III by desulfated heparin compounds may correlate with the presence of clusters of acidic amino acid residues ETFEV and SPDADPE flanking the C-III cluster (133-RFYRRGRFR-141; see Table I). Since HS chains are known to be composed of blocks of virtually nonsulfated disaccharide units that alternate with stretches of moderately/extensively sulfated disaccharides, it is likely that acidic residues may direct, due a low charge repulsion with weakly sulfated blocks of HS, the 133-RFYRRGRFR-141 cluster toward interaction with somewhat more restricted sequences within HS chain. For the same reason PrV580 gC may, to some extent, be repulsed by native heparin in which sulfate groups are known to be evenly distributed over the chain. It should be noted that in contrast to PrV580C-III, the clusters of negatively charged amino acids are not present near the dominant HS-binding sequences in PrV581C-II and PrV582C-I. It has been recently suggested that the ability of some chemokines to interact with subfractions of heparin correlated with the presence of acidic residues within a putative heparin/HS-binding domain (34).

Yet another pattern of sensitivity to desulfated heparin samples was observed with remaining mutant PrV582C-I. While selective N-desulfation of heparin had no effect, 2-O- or 6-O-desulfation decreased an ability of heparin to inhibit PrV582C-I attachment to cells. This suggests that the binding of PrV582C-1 is more dependent on the O-sulfates than N-sulfates. In addition gC purified from PrV582C-1 less efficiently than gC of the other mutants bound heparin oligosaccharides; an extensive binding was not demonstrated, even with the longest oligosaccharide fragments.

Although each of the specific HS-binding clusters of gC could separately support efficient PrV attachment to cells, we found that in comparison with wild-type PrV gC, PrV581C-II gC bound ~three times less and gCs of PrV580C-III and PrV582C-I bound ~four to five times less of HS isolated from MDBK cells. Thus, it is likely that the individual HS binding capacities of the respective clusters could potentiate through an additive or synergistic effects an overall HS binding capacity of wild-type gC. Further insight into functional significance of specific HS-binding cluster of PrV gC was obtained in the experiments of PrV attachment to cells digested with HS-degrading enzymes. Both PrV582C-I and PrV580C-III poorly attached to cells pretreated with certain, relatively low, enzyme amounts, whereas under the same conditions the binding of PrV581C-II and wild-type PrV was unaffected. Since similar tendencies were observed with both heparinase that cleaves HS chain in regions of high sulfation, i.e. containing GlcNSO3(±6-OSO3)-Ido(2-SO3) disaccharides and heparitinase, which attacks HS stretches of low sulfation at hexosaminidic linkages adjacent to glucuronic acid residue, it is likely that truncated chains of HS that remained on proteoglycan core following enzyme treatment of cells poorly interacted with PrV582C-I and PrV580C-III. It is perhaps interesting to note that these two mutants required relatively long heparin fragments for efficient binding. These results also suggest that the HS-binding subunits of gC, although seemingly redundant with respect to PrV binding to in vitro cultured cells, may facilitate PrV infection of cells that express low amounts or undersulfated HS. It is known that HS expressed on the surfaces of different cells may differ with respect to the overall quantity produced, chain length, and its fine structure (35, 36). PrV infection in vivo frequently concerns polarized cells. It has been shown that the specific sorting mechanisms in certain polarized cells may favor a low expression of HS on the apical surface (37).

The molecular model of some heparin/HS-binding proteins revealed that discrete clusters of basic residues, or the same clusters originating from separate monomers of a particular protein, frequently juxtapose each other to form an elongated domain that could favorably accommodate linear blocks of HS/heparin chain (15, 16, 38). If this is the case also with PrV gC, then mutant viruses that retain only singular cluster might preferably accommodate shorter fragments of heparin oligosaccharides than wild-type gC that contains three distinct clusters. However direct binding experiments revealed that wild-type gC bound much shorter oligosaccharides than PrV582C-I and PrV580C-III and only slightly shorter fragments of heparin than PrV581C-II gC. Thus, either spatial arrangement of all three clusters endows wild-type gC with flexibility to adopt relatively short heparin fragments or the C-II cluster plays a dominant role. In this respect it is noteworthy that PrV581C-II attached to heparinase/heparitinase-treated cells almost as efficiently as wild-type virus. This suggests that some important attachment functions related to efficient binding to HS are, at least in part, retained in PrV581C-II gC. However, competition experiments suggested that the binding of this mutant to cells may, in contrast to wild-type virus, require more densely sulfated stretches of HS. Based on this we postulate that the C-II cluster may represent the main HS-binding site of PrV gC, supporting virus attachment to short, heparin-like stretches within HS chains. The likely function of the C-I and C-III clusters, which exhibited clearly different binding preferences, would be to increase gC ability to bind to different structural features or regions within the HS chain including those of low/moderate sulfation. The molecular model of lipoprotein lipase revealed that several clusters of basic residues were congregated on one face of the molecule (16). Based on this as well as on the results of mutational analysis of lipoprotein lipase (39, 40), it was proposed (16) that the ensemble of clusters may be involved in vivo in interaction with HS and that the domination of a specific cluster may depend on the nature of available HS chain. For the virus it would be of benefit to adopt to different types of host cell HS by having suitable adapter molecules for different HS motifs. Finally, several abilities of different PrV mutants, such as attachment to heparitinase/heparinase-treated cells, binding to heparin oligosaccharides, and binding to isolated HS correlated with the values of their specific infectivity. This indicates that the specific interaction of PrV with HS is important for an efficient infection of cells by the virus.

    FOOTNOTES

* This work was supported by grants from the Mizutani Foundation for Glycoscience, the Scandinavian Society of Chemotherapy, Centrala Försöksdjursnämnden (to T. B.), the Swedish Medical Research Council (number 9489 (to B. S) and number 2309 (to support D. S.)), Polysackaridforskning AB (to D. S.), Sahlgren's University Hospital Läkarutbildningsavtal grants (to T. B. and B. S.), and the National Institute of Allergy and Infectious Diseases (to P. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Clinical Virology, University of Göteborg, Guldhedsgatan 10B, S-413 46, Göteborg, Sweden. Tel.: 46-31-604735; Fax: 46-31-604960; E-mail: tomas.bergstrom{at}microbio.gu.se.

1 The abbreviations used are: HS, heparan sulfate; PrV, pseudorabies virus; PrV-Be, pseudorabies virus Becker strain; gC, glycoprotein C; C-I, cluster I; C-II, cluster II; C-III, cluster III; PBS, phosphate-buffered saline; BSA, bovine serum albumin; EMEM, Eagle's minimum essential medium; RK-13, rabbit kidney; MDBK, Madin-Darby bovine kidney; pfu, plaque-forming unit(s).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. WuDunn, D., and Spear, P. G. (1989) J. Virol. 63, 52-58[Medline] [Order article via Infotrieve]
  2. Mettenleiter, T. C., Zsak, L., Zuckermann, F., Sugg, N., Kern, H., and Ben-Porat, T. (1990) J. Virol. 64, 278-286[Medline] [Order article via Infotrieve]
  3. Okazaki, K., Mitsuzaki, T., Sugahara, Y., Okada, J., Hasebe, M., Iwamura, Y., Ohnishi, M., Kanno, T., Shimizu, M., Honda, E., and Kono, Y. (1991) Virology 181, 666-670[Medline] [Order article via Infotrieve]
  4. Liang, X., Babiuk, L., and Zamb, T. (1991) J. Virol. 65, 5553-5557[Medline] [Order article via Infotrieve]
  5. Zhu, Z., Gerson, M. D., Ambron, R., Gabel, Ch, and Gerson, A. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3546-3550[Abstract]
  6. Compton, T., Nowlin, D., and Cooper, N. R. (1993) Virology 193, 834-841[CrossRef][Medline] [Order article via Infotrieve]
  7. Kari, B., and Gehrz, R. (1993) J. Gen. Virol. 74, 255-264[Abstract]
  8. Vanderplasschen, A., Bublot, M., Dubuisson, J., Pastoret, P. P., Thiry, E. (1993) Virology 196, 232-240[CrossRef][Medline] [Order article via Infotrieve]
  9. Lycke, E., Johansson, M., Svennerholm, B., and Lindahl, U. (1991) J. Gen. Virol. 72, 1131-1137[Abstract]
  10. Herold, B. C., Gerber, S. I., Belval, B. J., Siston, A. M., Shulman, N. (1996) J. Virol. 70, 3461-3469[Abstract]
  11. Herold, B. C., Gerber, S. I., Polonsky, T., Belval, B. J., Shaklee, P. N., Holme, K. (1995) Virology 206, 1108-1116[CrossRef][Medline] [Order article via Infotrieve]
  12. Trybala, E., Bergström, T., Spillmann, D., Svennerholm, B., Olofsson, S., Flynn, S. J., Ryan, P. (1996) Virology 218, 35-42[CrossRef][Medline] [Order article via Infotrieve]
  13. Cardin, A. D., and Weintraub, H. J. R. (1989) Arteriosclerosis 9, 21-32[Abstract]
  14. Spillmann, D., and Lindahl, U. (1994) Curr. Opin. Struct. Biol. 4, 677-682
  15. Mann, D. M., Romm, E., and Migliorni, M. (1994) J. Biol. Chem. 269, 23661-23667[Abstract/Free Full Text]
  16. van Tilbeurgh, H., Roussel, A., Lalouel, J.-M., and Cambillau, C. (1994) J. Biol. Chem. 269, 4626-4633[Abstract/Free Full Text]
  17. Faham, S., Hileman, R. E., Fromm, J. R., Linhardt, R. J., Rees, D. C. (1996) Science 271, 1116-1120[Abstract]
  18. Mourey, L., Samama, J.-P., Delarue, M., Petitou, M., Choay, J., and Moras, D. (1993) J. Mol. Biol. 232, 223-241[CrossRef][Medline] [Order article via Infotrieve]
  19. Karger, A., Saalmuller, A., Tufaro, F., Banfield, B. W., Mettenleiter, T. C. (1995) J. Virol. 69, 3482-3489[Abstract]
  20. Zsak, L., Sugg, N., Ben-Porat, T., Robins, A. K., Whealy, M. E., Enquist, L. W. (1991) J. Virol. 65, 4317-4324[Medline] [Order article via Infotrieve]
  21. Flynn, S. J., Burgett, B. L., Stein, D. S., Wilkinson, K. S., Ryan, P. (1993) J. Virol. 67, 2646-2654[Abstract]
  22. Flynn, S. J., and Ryan, P. (1996) J. Virol. 70, 1355-1364[Abstract]
  23. Robbins, A. K., Weis, J. H., Enquist, L. W., Watson, R. J. (1984) J. Mol. Appl. Genet. 2, 485-496[Medline] [Order article via Infotrieve]
  24. Lindahl, U., Cifonelli, J. A., Lindahl, B., and Rodén, L. (1965) J. Biol. Chem. 240, 2817-2820[Free Full Text]
  25. Jaseja, M., Rej, R. N., Sauriol, F., and Perlin, A. (1989) Can. J. Chem. 67, 1449-1456
  26. Inoue, Y., and Nagasawa, K. (1976) Carbohydr. Res. 46, 87-95[CrossRef][Medline] [Order article via Infotrieve]
  27. Nagasawa, K., Inoue, Y., and Kamata, T. (1977) Carbohydr. Res. 58, 47-55[CrossRef][Medline] [Order article via Infotrieve]
  28. Lloyd, A. G., Embery, G., and Fowler, L. J. (1971) Biochem. Pharmacol. 20, 637-648[CrossRef][Medline] [Order article via Infotrieve]
  29. Danishefsky, I., and Steiner, H. (1965) Biochim. Biophys. Acta 101, 37-45[Medline] [Order article via Infotrieve]
  30. Pejler, G., Lindahl, U., Larm, O., Scholander, E., Sandgren, E., and Lundblad, A. (1988) J. Biol. Chem. 263, 5197-5201[Abstract/Free Full Text]
  31. Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J. T. (1994) J. Biol. Chem. 269, 11216-11223[Abstract/Free Full Text]
  32. Coe, N. E., and Mengeling, W. L. (1990) Arch. Virol. 110, 137-142[Medline] [Order article via Infotrieve]
  33. Maccarana, M., Casu, B., and Lindahl, U. (1993) J. Biol. Chem. 268, 23898-23905[Abstract/Free Full Text]
  34. Witt, D. P., and Lander, A. D. (1994) Curr. Biol. 4, 349-400
  35. Gallagher, J. T., Lyon, M., and Steward, W. P. (1986) Biochem. J. 236, 313-325[Medline] [Order article via Infotrieve]
  36. Gallagher, J. T., and Walker, A. (1985) Biochem. J. 230, 665-674[Medline] [Order article via Infotrieve]
  37. Martens, G., Van der Schueren, B., Van der Berghe, H., David, G. (1996) J. Cell Biol. 132, 487-497[Abstract]
  38. Stuckey, J. A., St.-Charles, R., and Edwards, B. F. (1992) Proteins Struct. Funct. Genet. 14, 277-287 [Medline] [Order article via Infotrieve]
  39. Hata, A., Ridinger, D. N., Sutherland, S., Emi, M., Shuhua, Z., Myers, R. L., Ren, K., Cheng, T., Inoue, I., Wilson, D. E., Iverius, P.-H., Lalouel, J.-M. (1993) J. Biol. Chem. 268, 8447-8457[Abstract/Free Full Text]
  40. Davis, R. C., Wong, H., Nikazy, J., Wang, K., Han, Q., and Schotz, M. C. (1992) J. Biol. Chem. 267, 21499-21504[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.